AHA Scientific Sessions 2026 Abstract · Nov 2, 2026
Factors Associated with Enhanced LDL-C Lowering with Bempedoic Acid and Bempedoic Acid Plus Ezetimibe in Routine Practice
By Shapiro MD, Coleman CI, Nelson J et al.
Introduction: Bempedoic acid (BA) has been proven to reduce CV risk among patients with statin intolerance and patients on maximally tolerated statins in clinical trials. Identifying factors that may be associated with enhanced response to BA with and without ezetimibe (BA+EZE) in routine practice may help with clinical prioritization of these therapies. Research Question: What factors are associated with an enhanced LDL-C lowering response of ≥30% in patients starting BA or BA+EZE? Methods: This study used the Veradigm Network EHR linked to Komodo Health claims to identify adults starting BA or BA+EZE (index) from 01/01/2022 to 10/31/2025. Inclusion criteria required ≥1 LDL-C result within 6 months before or on the index and ≥1 LDL-C result up to 2 years post-index. Patients were also required to have continuous use of index therapy (<60-day fill gap) up to the earliest follow-up LDL-C result. Patients with EZE in the 30 days pre-index were included in the BA cohort. Factors associated with a clinically relevant ≥30% reduction (comparable to that observed with moderate-intensity statins) from baseline to the first follow-up LDL-C value were identified using multivariable logistic regression (adjusted odds ratio [aOR]). Results: A total of 4,942 new initiators (BA: 3,204; BA+EZE: 1,738) were included. Most patients were ≥60 years of age (73.2%), female (57.2%), and White (67.5%). Baseline comorbidities included history of ASCVD (52.5%), diabetes (41.8%), hypertension (74.3%), and BMI ≥30 kg/m ² (45.7%). In the 12-month baseline, most patients took statins (any dose) (63.3%); 41.7% were on EZE. More specifically, in the 30 days pre-index, 41.3% were on statins and 47.1% of BA patients were on EZE. Baseline median (IQR) LDL-C was 122.0 (91-154) mg/dL for BA and 127.0 (94-161) mg/dL for BA+EZE. In follow-up, ≥30% LDL-C reductions were achieved by 42.4% of patients overall; 37.4% of BA initiators (median LDL-C reduction by 12 months: 32.8%) and 51.7% of BA+EZE initiators (median LDL-C reduction by 12 months: 41.7%). Characteristics associated with an enhanced LDL-C response were combo BA+EZE initiation (vs starting BA) (aOR [CI 95% ]: 2.43 [2.10-2.82]), no statin use in the 12-month baseline (vs moderate-intensity) (aOR [CI 95% ]: 1.26 [1.07-1.47]), and baseline LDL-C per 10 mg/dL increase (aOR [CI 95% ]: 1.15 [1.13-1.17]). Among BA users, EZE use in the 30 days pre-index (aOR[CI 95% ]: 1.81 [1.55-2.11]) was associated with greater likelihood of achieving ≥30% LDL-C reduction. Conclusion: In this real-world cohort, combo BA+EZE therapy, absence of statin use (in 12-month baseline), baseline LDL-C (per 10 mg/dL increase), and EZE use among BA patients (in the 30 days pre-index) were associated with an increased odds of obtaining a ≥30% LDL-C reduction. Understanding factors associated with enhanced response may help clinicians identify patients who may see additional LDL-C lowering with BA or BA+EZE.